April 2005 (Basel, Switzerland)
Background
Over the last decade, the pharmaceutical industry has witnessed transformations that have enhanced the global reach of major players; and whilst new rules have been established to regulate some aspects of the pharmaceutical business, developments in biology and genomics have revolutionised the drug discovery process and culture within the industry. All these developments present both opportunities and pressures for companies and test the limits of current regulatory processes.
Furthermore, in the face of growing criticism about its handling of negative results from clinical trials, its relations with developing countries, or about how it markets and educates doctors and interacts with researchers, the pharmaceutical industry is being more closely scrutinised than ever before, by regulators and the public.
Objectives
The conference on “Self Regulation in the Pharmaceutical Industry: What can it achieve?”, organised by the Basel Institute on Governance on 21 April 2005, presented a unique opportunity for participants to learn about the current state of the debate on how the pharmaceutical industry should be regulated. In particular it aimed to understand who should ideally decide the form, scope and content of regulation, whether public trust could be rebuilt so that mechanisms of self regulation could be used, or whether the moment has come for government intervention.
Programme
> Download as PDF (44 kb)
Speakers
> Downloas as PDF (60 kb)